Request Deal Involvement
Castle Biosciences completed the acquisition of Myriad myPath® Melanoma from Myriad Genetics for $32.5m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Cooley
or
Principals
vendor
MYRIAD GENETICS
target
MYRIAD MYPATH MELANOMA LLC
bidder
CASTLE BIOSCIENCES INC
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2026 Datasite